Voyager Therapeutics (NASDAQ:VYGR) Now Covered by Guggenheim

Guggenheim began coverage on shares of Voyager Therapeutics (NASDAQ:VYGR) in a report issued on Tuesday, Marketbeat reports. The firm set a “buy” rating and a $22.00 price target on the stock. Guggenheim’s target price suggests a potential upside of 130.13% from the stock’s current price.

VYGR has been the subject of a number of other research reports. Wells Fargo & Company upgraded Voyager Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $9.00 to $14.00 in a report on Tuesday, January 2nd. Citigroup began coverage on Voyager Therapeutics in a research report on Thursday, March 7th. They issued a “buy” rating and a $16.00 target price on the stock. HC Wainwright began coverage on Voyager Therapeutics in a research report on Tuesday, March 19th. They issued a “buy” rating and a $30.00 target price on the stock. Finally, StockNews.com raised Voyager Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, March 9th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, Voyager Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $19.33.

Voyager Therapeutics Stock Performance

Shares of NASDAQ VYGR opened at $9.56 on Tuesday. The company has a market capitalization of $519.11 million, a P/E ratio of 3.09 and a beta of 0.96. The company’s 50 day moving average price is $8.33 and its 200-day moving average price is $7.84. Voyager Therapeutics has a 52-week low of $6.06 and a 52-week high of $14.34.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings data on Wednesday, February 28th. The company reported $1.25 EPS for the quarter, beating the consensus estimate of ($0.59) by $1.84. The business had revenue of $90.06 million for the quarter, compared to the consensus estimate of $4.95 million. Voyager Therapeutics had a net margin of 52.93% and a return on equity of 63.89%. Analysts forecast that Voyager Therapeutics will post -1.64 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in VYGR. Ameritas Investment Partners Inc. purchased a new position in Voyager Therapeutics in the 2nd quarter worth approximately $30,000. Gladius Capital Management LP bought a new stake in Voyager Therapeutics during the third quarter valued at about $25,000. AJOVista LLC bought a new stake in Voyager Therapeutics during the fourth quarter valued at about $39,000. UBS Group AG acquired a new stake in Voyager Therapeutics in the first quarter worth about $39,000. Finally, China Universal Asset Management Co. Ltd. purchased a new position in shares of Voyager Therapeutics in the fourth quarter worth about $43,000. 48.03% of the stock is owned by hedge funds and other institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.